Atrophic Vaginitis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Cream USP, 0.01% (Teva Pharmaceuticals, USA) to Estrace® Estradiol Vaginal Cream, USP, 0.01% (Warner Chilcott) in the Treatment of Atrophic Vaginitis
The objectives of this study were to evaluate the therapeutic equivalence of the Test formulation, generic Estradiol Vaginal Cream United States Pharmacopoeia (USP), 0.01% (Teva Pharmaceuticals, United States of America) to the marketed product, Estrace® Cream estradiol vaginal cream USP, 0.01% (Warner Chilcott) in participants with atrophic vaginitis; to demonstrate the superiority of the Test and Reference (active) treatments over Placebo (vehicle) cream in participants with atrophic vaginitis; and to compare the safety of Test, Reference, and Placebo treatments in participants with atrophic vaginitis.
Systemic (oral or transdermal patch administration) estrogen therapies have been shown to effectively treat symptoms of atrophic vaginitis but bear undesirable side effects including increased risk of heart attacks, stroke, endometrial cancer, and breast cancer. Topical therapies (creams and transvaginal delivery systems) provide low doses of estrogen to the vaginal mucosa to provide local relief for the symptoms of atrophic vaginitis, while reducing the unwanted side effects associated with systemic delivery systems. Low dose, topical estrogen therapy is considered most appropriate and convenient for the treatment of vaginal symptoms associated with menopause, particularly when other symptoms including bone loss or vasomotor dysfunction do not need to be targeted. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00984399 -
Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
|
N/A | |
Completed |
NCT04079218 -
Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
|
Phase 4 | |
Recruiting |
NCT05953090 -
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
|
N/A | |
Terminated |
NCT00816556 -
A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis
|
Phase 3 | |
Completed |
NCT00167921 -
Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis
|
Phase 1 | |
Completed |
NCT04327947 -
Evaluation of Gynecological Acceptability of 3 Health Care Products
|
N/A | |
Recruiting |
NCT05118685 -
Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis
|
Phase 1 | |
Completed |
NCT05058313 -
Evaluation of the Safety and Performance of the MILTA GYNECO Vaginal Probe in Postmenopausal Women With Vaginal Atrophy
|
N/A | |
Completed |
NCT02691936 -
Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy
|
N/A | |
Completed |
NCT02995694 -
A Study Comparing Estradiol Vaginal Cream to Estrace® Cream in Females With Atrophic Vaginitis
|
Phase 3 | |
Recruiting |
NCT06305494 -
Genitourinary Syndrome of Menopause in Thai Gynecologic Cancer Survivors
|
||
Completed |
NCT02195986 -
A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
|
Phase 3 | |
Recruiting |
NCT03981458 -
Hyaluronate for the Treatment and Prevention of Recurrent Urinary Tract Infection in Women Suffering Atrophic Vaginitis
|
N/A | |
Completed |
NCT05396261 -
a Flexible Wound Dressing for the Management of Genital Skin Conditions
|
N/A | |
Completed |
NCT02869165 -
Vaginal and Urinary Microbiome Trial
|
Phase 4 | |
Completed |
NCT02029053 -
Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness
|
Phase 0 | |
Not yet recruiting |
NCT06176820 -
Vaginal Hyaluronic Acid, Arginine and Liposome Gel Versus Vaginal Lubricant in Postmenopausal Women With Genitourinary Syndrome of Menopause
|
Phase 2/Phase 3 | |
Recruiting |
NCT02733731 -
The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis
|
Phase 1 | |
Withdrawn |
NCT02460302 -
Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy
|
Phase 2 | |
Completed |
NCT02313545 -
Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of AV and DIV
|
Phase 1/Phase 2 |